KKR Takes Integer Holdings Private at $5.7B, Betting on Medical Device Contract Manufacturing Scale

KKR closed an all-cash acquisition of Integer Holdings for $5.7 billion, removing the medical device contract development and manufacturing organization from public markets in a single transaction. The deal prices Integer's specialized manufacturing footprint—cardiovascular rhythm management, neuromodulation, and orthopedic device assembly—at a premium to comparable publicly traded CDMOs, reflecting KKR's thesis that regulated production capacity commands infrastructure-like returns when paired with long-term OEM contracts.

Integer operates 28 manufacturing facilities across the United States, Mexico, Europe, and Asia, serving major medical device OEMs under multi-year supply agreements. The company generated roughly $1.6 billion in trailing revenue, with 72% derived from cardiovascular devices and the remainder split between orthopedic and portable medical components. KKR's purchase values Integer at approximately 3.6x trailing revenue, in line with recent private equity acquisitions of scaled manufacturing platforms in the life sciences sector. The firm paid cash, bypassing any equity rollover or earnout structure, a signal that KKR views Integer's contract book as stable enough to support leverage without operational risk-sharing.

The transaction matters because it confirms a structural shift in how private equity treats medical device supply chains. Integer is not a high-growth SaaS business or a distressed turnaround; it is a capital-intensive, margin-stable contract manufacturer with sticky customer relationships and regulatory barriers to entry. KKR's willingness to deploy $5.7 billion in equity and debt capital reflects a bet that device OEMs will continue to outsource complex manufacturing rather than build in-house capacity, especially as FDA and international regulatory requirements grow more onerous. Integer's existing customer base includes multi-billion-dollar medical technology companies locked into supply agreements that span product life cycles measured in decades, not quarters.

For allocators, the secondary implication is valuation compression in publicly traded CDMO peers. Integer's exit multiple sets a ceiling for comparable businesses still trading on public markets, particularly those without Integer's scale in cardiovascular manufacturing. The deal also removes a benchmark from the Russell 2000, reducing visibility into contract manufacturing economics for investors who track the sector through public comps. KKR's move follows a pattern: acquire a subscale but profitable industrial platform, apply operational improvements funded by lower-cost private capital, then hold or exit to a strategic buyer once margin expansion has been wrung out. Integer's 18% EBITDA margin leaves room for KKR to tighten procurement, consolidate facilities, and improve throughput without jeopardizing OEM relationships.

Operators should monitor whether KKR pushes Integer toward higher-mix neuromodulation manufacturing, a segment with better margins than cardiovascular rhythm management but shorter contract durations. Any shift in customer concentration—Integer's top 10 customers represent roughly 60% of revenue—would signal a strategic pivot rather than steady-state management. The deal also sets a comp for other mid-cap medical device suppliers considering take-private offers; expect banker pitches to reference Integer's exit multiple as a floor for negotiation. If KKR files to take Integer public again within 36 to 48 months, it will confirm that the firm saw this as a short-hold compression play rather than a long-duration infrastructure asset.

Integer's largest OEM customer, Medtronic, has not yet commented on supply continuity under KKR ownership, but contract provisions typically require advance notice of ownership changes and allow renegotiation of pricing terms. That conversation will determine whether KKR can hold margins or must concede economics to retain the contract book.